CoChat
Sign Up
Cited by 101Diabetes Treatment and ManagementDiabetes Management and ResearchDiabetes, Cardiovascular Risks, and Lipoproteins

Consensus recommendations on sulfonylurea and sulfonylurea combinations in the management of type 2 diabetes mellitus - international task force

Open access
Kalra, Sanjay, Bahendeka, Silver, Sahay, Rakesh, Ghosh, Sujoy, Md, Fariduddin, Orabi, Abbas, Ramaiya, Kaushik, Al Shammari, Sameer +23 more·2018·Indian Journal of Endocrinology and Metabolism
DOI 10.4103/ijem.ijem_556_17PMC PMC5838894
Open this paper in CoChat — free account

Abstract

For decades, sulfonylureas (SUs) have been important drugs in the antidiabetic therapeutic armamentarium. They have been used as monotherapy as well as combination therapy. Focus on newer drugs and concerns about the risk of severe hypoglycemia and weight gain with some SUs have led to discussion on their safety and utility. It has to be borne in mind that the adverse events associated with SUs should not be ascribed to the whole class, as many modern SUs, such as glimepiride and gliclazide modified release, are associated with better safety profiles. Furthermore, individualization of treatment, using SUs in combination with other drugs, backed with careful monitoring and patient education, ensures maximum benefits with minimal side effects. The current guidelines, developed by experts from Africa, Asia, and the Middle East, promote the safe and smart use of SUs in combination with other glucose-lowering drugs.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.4103/ijem.ijem_556_17

Cites

12 of 12 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Cites

Flagged first, then by citations

Research works printed but not linked: 159

  1. [4]Agarwal AA Jadhav PR Deshmukh YA Prescribing pattern and efficacy of anti-diabetic drugs in maintaining optimal glycemic levels in diabetic patients J Basic Clin Pharm 2014 5 79 83 25278671 PMC4160724
  2. [5]Kalra S Aamir AH Raza A Das AK Azad Khan AK Shrestha D Place of sulfonylureas in the management of type 2 diabetes mellitus in south Asia: A consensus statement Indian J Endocrinol Metab 2015 19 577 96 26425465 PMC4566336
  3. [6]Truter I An investigation into antidiabetic medication prescribing in South Africa J Clin Pharm Ther 1998 23 417 22 10048502
  4. [7]Chiang CW Chiu HF Chen CY Wu HL Yang CY Trends in the use of oral antidiabetic drugs by outpatients in Taiwan: 1997-2003 J Clin Pharm Ther 2006 31 73 82 16476123
  5. [12]Cahn A Cefalu WT Clinical considerations for use of initial combination therapy in type 2 diabetes Diabetes Care 2016 39 Suppl 2 S137 45 27440826 PMC5023033
  6. [14]Phung OJ Sobieraj DM Engel SS Rajpathak SN Early combination therapy for the treatment of type 2 diabetes mellitus: Systematic review and meta-analysis Diabetes Obes Metab 2014 16 410 7 24205921
  7. [15]Holman RR Paul SK Bethel MA Matthews DR Neil HA 10-year follow-up of intensive glucose control in type 2 diabetes N Engl J Med 2008 359 1577 89 18784090
  8. [16]Derosa G Sibilla S Optimizing combination treatment in the management of type 2 diabetes Vasc Health Risk Manag 2007 3 665 71 18078018 PMC2291311
  9. [18]Del Prato S Felton AM Munro N Nesto R Zimmet P Zinman B Improving glucose management: Ten steps to get more patients with type 2 diabetes to glycaemic goal Int J Clin Pract 2005 59 1345 55 16236091
  10. [19]Abrahamson MJ Should sulfonylureas remain an acceptable first-line add-on to metformin therapy in patients with type 2 diabetes? Yes, they continue to serve us well!iabetes Care 2015 38 166 9 25538313
  11. [20]Handelsman Y Bloomgarden ZT Grunberger G Umpierrez G Zimmerman RS Bailey TS American Association of clinical endocrinologists and American College of endocrinology – Clinical practice guidelines for developing a diabetes mellitus comprehensive care plan-2015 Endocr Pract 2015 21 Suppl 1 1 87 25869408 PMC4959114
  12. [21]Aquilante CL Sulfonylurea pharmacogenomics in type 2 diabetes: The influence of drug target and diabetes risk polymorphisms Expert Rev Cardiovasc Ther 2010 8 359 72 20222815 PMC2860269
  13. [22]White JR Jr A brief history of the development of diabetes medications Diabetes Spectr 2014 27 82 6 26246763 PMC4522877
  14. [23]Quianzon CC Cheikh IE History of current non-insulin medications for diabetes mellitus J Community Hosp Intern Med Perspect 2012 2 1 4 PMC3714066 23882374
  15. [24]Sarkar A Tiwari A Bhasin PS Mitra M Pharmacological and pharmaceutical profile of gliclazide: A review J Appl Pharm Sci 2011 1 11 9
  16. [25]Oderda G Richards K Turpin S Sulfonylurea Agents & Combination Products Drug Class Review University of Utah College of Pharmacy 2013 7 Final Report
  17. [27]Ballagi-Pordány G Németh M Aranyi Z Kékesi E Koltai MZ Papp G Effect of glimepiride on the electrical activity of isolated rabbit heart muscle Arzneimittelforschung 1992 42 111 3 1610416
  18. [28]Nakamura I Oyama J Komoda H Shiraki A Sakamoto Y Taguchi I Possible effects of glimepiride beyond glycemic control in patients with type 2 diabetes: A preliminary report Cardiovasc Diabetol 2014 13 15 24423092 PMC3909938
  19. [29]Ashcroft FM Gribble FM Tissue-specific effects of sulfonylureas: Lessons from studies of cloned K(ATP) channels J Diabetes Complications 2000 14 192 6 11004427
  20. [30]Gribble FM Ashcroft FM Sulfonylurea sensitivity of adenosine triphosphate-sensitive potassium channels from beta cells and extrapancreatic tissues Metabolism 2000 49 3 6 11078468
  21. [31]Vila-Carriles WH Zhao G Bryan J Defining a binding pocket for sulfonylureas in ATP-sensitive potassium channels FASEB J 2007 21 18 25 17110465
  22. [32]Thulé PM Umpierrez G Sulfonylureas: A new look at old therapy Curr Diab Rep 2014 14 473 24563333
  23. [33]Kramer W Müller G Girbig F Gutjahr U Kowalewski S Hartz D Differential interaction of glimepiride and glibenclamide with the beta-cell sulfonylurea receptor. II. Photoaffinity labeling of a kDa protein by [3H] glimepiride glimepiride Biochim Biophys Acta 1994 1191 278 90 8172913
  24. [34]Briscoe VJ Griffith ML Davis SN The role of glimepiride in the treatment of type 2 diabetes mellitus Expert Opin Drug Metab Toxicol 2010 6 225 35 20055691
  25. [35]Holstein A Plaschke A Egberts EH Lower incidence of severe hypoglycaemia in patients with type 2 diabetes treated with glimepiride versus glibenclamide Diabetes Metab Res Rev 2001 17 467 73 11757083
  26. [36]Singh AK Singh R Is gliclazide a sulfonylurea with difference? A review in 2016 Expert Rev Clin Pharmacol 2016 9 839 51 26924475
  27. [37]Halimi S Schweizer A Minic B Foley J Dejager S Combination treatment in the management of type 2 diabetes: Focus on vildagliptin and metformin as a single tablet Vasc Health Risk Manag 2008 4 481 92 18827867 PMC2515409
  28. [39]Basit A Riaz M Fawwad A Glimepiride: Evidence-based facts, trends, and observations (GIFTS). [corrected] Vasc Health Risk Manag 2012 8 463 72 23028231 PMC3448454
  29. [41]Garber AJ Abrahamson MJ Barzilay JI Blonde L Bloomgarden ZT Bush MA Consensus statement by the American association of clinical endocrinologists and American college of endocrinology on the comprehensive type 2 diabetes management algorithm-2017 executive summary Endocr Pract 2017 23 207 38 28095040
  30. [48]International Diabetes Federation Guideline Development Group Global guideline for type 2 diabetes Diabetes Res Clin Pract 2014 104 1 52 24508150
  31. [51]Mishra S Ray S Dalal JJ Sawhney JP Ramakrishnan S Nair T Management protocols of stable coronary artery disease in India: Executive summary Indian Heart J 2016 68 868 73 27931562 PMC5143826
  32. [57]Del Prato S Vigili de Kreutzenberg S Riccio A Tiengo A Hepatic sensitivity to insulin: Effects of sulfonylurea drugs Am J Med 1991 29S 36S 1872301
  33. [59]Bolen S Tseng E Hutfless S Segal JB Suarez-Cuervo C Berger Z Diabetes Medications for Adults with Type 2 Diabetes: An Update 2016 Last accessed on 2017 Jan 12 Rockville (MD) Agency for Healthcare Research and Quality (US) Available from: http://www.ncbi.nlm.nih.gov/books/NBK362863/ 27227214
  34. [60]Hirst JA Farmer AJ Dyar A Lung TW Stevens RJ Estimating the effect of sulfonylurea on hbA1c in diabetes: A systematic review and meta-analysis Diabetologia 2013 56 973 84 23494446 PMC3622755
  35. [61]Ahrén B Johnson SL Stewart M Cirkel DT Yang F Perry C HARMONY 3: 104-week randomized, double-blind, placebo- and active-controlled trial assessing the efficacy and safety of albiglutide compared with placebo, sitagliptin, and glimepiride in patients with type 2 diabetes taking metformin Diabetes Care 2014 37 2141 8 24898304
  36. [62]Kim HS Kim DM Cha BS Park TS Kim KA Kim DL Efficacy of glimepiride/metformin fixed-dose combination vs. metformin uptitration in type 2 diabetic patients inadequately controlled on low-dose metformin monotherapy: A randomized, open label, parallel group, multicenter study in Korea J Diabetes Investig 2014 5 701 8 PMC4234234 25422771
  37. [63]Kalra S Das AK Epidemiologic surveillance of glycemic response to a scored, breakable, extended release, fixed dose combination of gliclazide and metformin in persons with type 2 diabetes J Assoc Physicians India 2017 65 38 41 28782312
  38. [64]Charpentier G Fleury F Kabir M Vaur L Halimi S Improved glycaemic control by addition of glimepiride to metformin monotherapy in type 2 diabetic patients Diabet Med 2001 18 828 34 11678974
  39. [65]González-Ortiz M Martínez-Abundis E Grupo para el Tratamiento de la Diabetes Mellitus con Combinaciones. Efficacy and safety of glimepiride plus metformin in a single presentation, as combined therapy, in patients with type 2 diabetes mellitus and secondary failure to glibenclamide, as monotherapy Rev Invest Clin 2004 56 327 33 15612515
  40. [66]Ristic S Collober-Maugeais C Cressier F Tang P Pecher E Nateglinide or gliclazide in combination with metformin for treatment of patients with type 2 diabetes mellitus inadequately controlled on maximum doses of metformin alone: 1-year trial results Diabetes Obes Metab 2007 9 506 11 17587393
  41. [67]Goldstein BJ Pans M Rubin CJ Multicenter, randomized, double-masked, parallel-group assessment of simultaneous glipizide/metformin as second-line pharmacologic treatment for patients with type 2 diabetes mellitus that is inadequately controlled by a sulfonylurea Clin Ther 2003 25 890 903 12852706
  42. [68]Feinglos M Dailey G Cefalu W Osei K Tayek J Canovatchel W Effect on glycemic control of the addition of 2.5 mg glipizide GITS to metformin in patients with T2DM Diabetes Res Clin Pract 2005 68 167 75 15860246
  43. [69]Marre M Howlett H Lehert P Allavoine T Improved glycaemic control with metformin-glibenclamide combined tablet therapy (Glucovance) in type 2 diabetic patients inadequately controlled on metformin Diabet Med 2002 19 673 80 12147149
  44. [70]Chien HH Chang CT Chu NF Hsieh SH Huang YY Lee IT Effect of glyburide-metformin combination tablet in patients with type 2 diabetes J Chin Med Assoc 2007 70 473 80 18063500
  45. [72]Umpierrez G Issa M Vlajnic A Glimepiride versus pioglitazone combination therapy in subjects with type 2 diabetes inadequately controlled on metformin monotherapy: Results of a randomized clinical trial Curr Med Res Opin 2006 22 751 9 16684436
  46. [73]Lee YK Song SO Kim KJ Cho Y Choi Y Yun Y Glycemic effectiveness of metformin-based dual-combination therapies with sulphonylurea, pioglitazone, or DPP4-inhibitor in drug-naïve Korean type 2 diabetic patients Diabetes Metab J 2013 37 465 74 24404518 PMC3881331
  47. [74]Matthews DR Charbonnel BH Hanefeld M Brunetti P Schernthaner G Long-term therapy with addition of pioglitazone to metformin compared with the addition of gliclazide to metformin in patients with type 2 diabetes: A randomized, comparative study Diabetes Metab Res Rev 2005 21 167 74 15386821
  48. [75]Mishriky BM Cummings DM Tanenberg RJ The efficacy and safety of DPP4 inhibitors compared to sulfonylureas as add-on therapy to metformin in patients with type 2 diabetes: A systematic review and meta-analysis Diabetes Res Clin Pract 2015 109 378 88 26059071
  49. [76]Zhou JB Bai L Wang Y Yang JK The benefits and risks of DPP4-inhibitors vs. sulfonylureas for patients with type 2 diabetes: Accumulated evidence from randomised controlled trial Int J Clin Pract 2016 70 132 41 26709610
  50. [77]Amate JM Lopez-Cuadrado T Almendro N Bouza C Saz-Parkinson Z Rivas-Ruiz R Effectiveness and safety of glimepiride and iDPP4, associated with metformin in second line pharmacotherapy of type 2 diabetes mellitus: Systematic review and meta-analysis Int J Clin Pract 2015 69 292 304 25683794 PMC5024024
  51. [78]Filozof C Gautier JF A comparison of efficacy and safety of vildagliptin and gliclazide in combination with metformin in patients with type 2 diabetes inadequately controlled with metformin alone: A 52-week, randomized study Diabet Med 2010 27 318 26 20536495
  52. [79]Göke B Gallwitz B Eriksson J Hellqvist A Gause-Nilsson I D1680C00001 Investigators Saxagliptin is non-inferior to glipizide in patients with type 2 diabetes mellitus inadequately controlled on metformin alone: A 52-week randomised controlled trial Int J Clin Pract 2010 64 1619 31 20846286
  53. [80]Thomsen RW Baggesen LM Søgaard M Pedersen L Nørrelund H Buhl ES Early glycaemic control in metformin users receiving their first add-on therapy: A population-based study of 4,734 people with type 2 diabetes Diabetologia 2015 58 2247 53 26277380
  54. [81]Ridderstråle M Andersen KR Zeller C Kim G Woerle HJ Broedl UC Comparison of empagliflozin and glimepiride as add-on to metformin in patients with type 2 diabetes: A 104-week randomised, active-controlled, double-blind, phase 3 trial Lancet Diabetes Endocrinol 2014 2 691 700 24948511
  55. [82]Cefalu WT Leiter LA Yoon KH Arias P Niskanen L Xie J Efficacy and safety of canagliflozin versus glimepiride in patients with type 2 diabetes inadequately controlled with metformin (CANTATA-SU): 52 week results from a randomised, double-blind, phase 3 non-inferiority trial Lancet 2013 382 941 50 23850055
  56. [83]Nauck MA Del Prato S Meier JJ Durán-García S Rohwedder K Elze M Dapagliflozin versus glipizide as add-on therapy in patients with type 2 diabetes who have inadequate glycemic control with metformin: A randomized, 52-week, double-blind, active-controlled noninferiority trial Diabetes Care 2011 34 2015 22 21816980 PMC3161265
  57. [84]Nauck M Frid A Hermansen K Thomsen AB During M Shah N Long-term efficacy and safety comparison of liraglutide, glimepiride and placebo, all in combination with metformin in type 2 diabetes: 2-year results from the LEAD-2 study Diabetes Obes Metab 2013 15 204 12 22985213
  58. [85]Yang W Chen L Ji Q Liu X Ma J Tandon N Liraglutide provides similar glycaemic control as glimepiride (both in combination with metformin) and reduces body weight and systolic blood pressure in Asian population with type 2 diabetes from China, South Korea and India: A 16-week, randomized, double-blind, active control trial(*) Diabetes Obes Metab 2011 13 81 8 21114607
  59. [86]Gitt AK Bramlage P Schneider S Tschöpe D A real world comparison of sulfonylurea and insulin vs. incretin-based treatments in patients not controlled on prior metformin monotherapy Cardiovasc Diabetol 2015 14 13 25645672 PMC4324641
  60. [87]Massi-Benedetti M Glimepiride in type 2 diabetes mellitus: A review of the worldwide therapeutic experience Clin Ther 2003 25 799 816 12852703
  61. [88]Green JB Feinglos MN Are sulfonylureas passé? Curr Diab Rep 2006 6 373 7 17076998
  62. [90]Zhang Y Hong J Chi J Gu W Ning G Wang W Head-to-head comparison of dipeptidyl peptidase-IV inhibitors and sulfonylureas – A meta-analysis from randomized clinical trials Diabetes Metab Res Rev 2014 30 241 56 24123720
  63. [91]Hissa MR Cavalcante LL Guimarães SB Hissa MN A 16-week study to compare the effect of vildagliptin versus gliclazide on postprandial lipoprotein concentrations and oxidative stress in patients with type 2 diabetes inadequately controlled with metformin monotherapy Diabetol Metab Syndr 2015 7 62 26170902 PMC4499917
  64. [92]Leiter LA Yoon KH Arias P Langslet G Xie J Balis DA Canagliflozin provides durable glycemic improvements and body weight reduction over 104 weeks versus glimepiride in patients with type 2 diabetes on metformin: A randomized, double-blind, phase 3 study Diabetes Care 2015 38 355 64 25205142
  65. [93]Derosa G Putignano P Bossi AC Bonaventura A Querci F Franzetti IG Exenatide or glimepiride added to metformin on metabolic control and on insulin resistance in type 2 diabetic patients Eur J Pharmacol 2011 666 251 6 21645507
  66. [94]Derosa G Maffioli P Salvadeo SA Ferrari I Ragonesi PD Querci F Exenatide versus glibenclamide in patients with diabetes Diabetes Technol Ther 2010 12 233 40 20151774
  67. [95]Moon JS Ha KS Yoon JS Lee HW Lee HC Won KC The effect of glargine versus glimepiride on pancreatic β-cell function in patients with type 2 diabetes uncontrolled on metformin monotherapy: Open-label, randomized, controlled study Acta Diabetol 2014 51 277 85 24445656
  68. [96]Chan SP Colagiuri S Systematic review and meta-analysis of the efficacy and hypoglycemic safety of gliclazide versus other insulinotropic agents Diabetes Res Clin Pract 2015 110 75 81 26361859
  69. [97]Andersen SE Christensen M Hypoglycaemia when adding sulphonylurea to metformin: A systematic review and network meta-analysis Br J Clin Pharmacol 2016 1291 302 27426428 PMC5061791
  70. [98]Schernthaner G Grimaldi A Di Mario U Drzewoski J Kempler P Kvapil M GUIDE study: Double-blind comparison of once-daily gliclazide MR and glimepiride in type 2 diabetic patients Eur J Clin Invest 2004 34 535 42 15305887
  71. [99]Del Prato S Nauck M Durán-Garcia S Maffei L Rohwedder K Theuerkauf A Long-term glycaemic response and tolerability of dapagliflozin versus a sulphonylurea as add-on therapy to metformin in patients with type 2 diabetes: 4-year data Diabetes Obes Metab 2015 17 581 90 25735400
  72. [100]Gallwitz B Guzman J Dotta F Guerci B Simó R Basson BR Exenatide twice daily versus glimepiride for prevention of glycaemic deterioration in patients with type 2 diabetes with metformin failure (EUREXA): An open-label, randomised controlled trial Lancet 2012 379 2270 8 22683137
  73. [101]Mamza J Mehta R Donnelly R Idris I Important differences in the durability of glycaemic response among second-line treatment options when added to metformin in type 2 diabetes: A retrospective cohort study Ann Med 2016 48 224 34 26982210
  74. [102]Dhindsa P Davis KR Donnelly R Comparison of the micro- and macro-vascular effects of glimepiride and gliclazide in metformin-treated patients with type 2 diabetes: A double-blind, crossover study Br J Clin Pharmacol 2003 55 616 9 12814458 PMC1884245
  75. [103]Schramm TK Gislason GH Vaag A Rasmussen JN Folke F Hansen ML Mortality and cardiovascular risk associated with different insulin secretagogues compared with metformin in type 2 diabetes, with or without a previous myocardial infarction: A nationwide study Eur Heart J 2011 32 1900 8 21471135
  76. [104]Mogensen UM Andersson C Fosbøl EL Schramm TK Vaag A Scheller NM Cardiovascular safety of combination therapies with incretin-based drugs and metformin compared with a combination of metformin and sulphonylurea in type 2 diabetes mellitus – A retrospective nationwide study Diabetes Obes Metab 2014 16 1001 8 24827939
  77. [105]Pfützner A Schöndorf T Tschöpe D Lobmann R Merke J Müller J PIOfix-study: Effects of pioglitazone/metformin fixed combination in comparison with a combination of metformin with glimepiride on diabetic dyslipidemia Diabetes Technol Ther 2011 13 637 43 21457065
  78. [106]Prentice JC Conlin PR Gellad WF Edelman D Lee TA Pizer SD Capitalizing on prescribing pattern variation to compare medications for type 2 diabetes Value Health 2014 17 854 62 25498781
  79. [107]Zhang H Zhang X Hu C Lu W Exenatide reduces urinary transforming growth factor-β1 and type IV collagen excretion in patients with type 2 diabetes and microalbuminuria Kidney Blood Press Res 2012 35 483 8 22687869
  80. [108]Palmer SC Mavridis D Nicolucci A Johnson DW Tonelli M Craig JC Comparison of clinical outcomes and adverse events associated with glucose-lowering drugs in patients with type 2 diabetes: A Meta-analysis JAMA 2016 316 313 24 27434443
  81. [109]Comaschi M Demicheli A Di Pietro C Bellatreccia A Mariz S COM06 Study Investigators Effects of pioglitazone in combination with metformin or a sulfonylurea compared to a fixed-dose combination of metformin and glibenclamide in patients with type 2 diabetes Diabetes Technol Ther 2007 9 387 98 17705695
  82. [110]Schernthaner G Durán-Garcia S Hanefeld M Langslet G Niskanen L Östgren CJ Efficacy and tolerability of saxagliptin compared with glimepiride in elderly patients with type 2 diabetes: A randomized, controlled study (GENERATION) Diabetes Obes Metab 2015 17 630 8 25761977
  83. [111]Ishii H Ohkubo Y Takei M Nishio S Yamazaki M Kumagai M Efficacy of combination therapy with sitagliptin and low-dose glimepiride in Japanese patients with type 2 diabetes J Clin Med Res 2014 6 127 32 24578754 PMC3935521
  84. [113]Yabe D Seino Y Dipeptidyl peptidase-4 inhibitors and sulfonylureas for type 2 diabetes: Friend or foe? J Diabetes Investig 2014 5 475 7 PMC4188101 25411611
  85. [114]McCluskey D Touger MS Melis R Schleusener DS McCluskey D Results of a randomized, double-blind, placebo-controlled study administering glimepiride to patients with type 2 diabetes mellitus inadequately controlled with rosiglitazone monotherapy Clin Ther 2004 26 1783 90 15639690
  86. [115]Chou HS Palmer JP Jones AR Waterhouse B Ferreira-Cornwell C Krebs J Initial treatment with fixed-dose combination rosiglitazone/glimepiride in patients with previously untreated type 2 diabetes Diabetes Obes Metab 2008 10 626 37 17645558
  87. [116]Hanefeld M Brunetti P Schernthaner GH Matthews DR Charbonnel BH QUARTET Study Group One-year glycemic control with a sulfonylurea plus pioglitazone versus a sulfonylurea plus metformin in patients with type 2 diabetes Diabetes Care 2004 27 141 7 14693980
  88. [117]Shimoda S Iwashita S Sekigami T Furukawa N Matsuo Y Ichimori S Comparison of the efficacy of sitagliptin and glimepiride dose-up in Japanese patients with type 2 diabetes poorly controlled by sitagliptin and glimepiride in combination J Diabetes Investig 2014 5 320 6 PMC4020337 24843781
  89. [118]Harashima SI Ogura M Tanaka D Fukushima T Wang Y Koizumi T Sitagliptin add-on to low dosage sulphonylureas: Efficacy and safety of combination therapy on glycaemic control and insulin secretion capacity in type 2 diabetes Int J Clin Pract 2012 66 465 76 22512606
  90. [119]Roberts VL Stewart J Issa M Lake B Melis R Triple therapy with glimepiride in patients with type 2 diabetes mellitus inadequately controlled by metformin and a thiazolidinedione: Results of a 30-week, randomized, double-blind, placebo-controlled, parallel-group study Clin Ther 2005 27 1535 47 16330290
  91. [120]Arai K Maeda H Sirabe S Yamamoto R Yamauchi M Hirao T Glimepiride strongly enhances the glucose-lowering effect in triple oral antidiabetes therapy with sitagliptin and metformin for Japanese patients with type 2 diabetes mellitus Diabetes Technol Ther 2013 15 335 41 23480592
  92. [121]Downes MJ Bettington EK Gunton JE Turkstra E Triple therapy in type 2 diabetes; a systematic review and network meta-analysis PeerJ 2015 3 e1461 26664803 PMC4675096
  93. [122]Derosa G Cicero AF D’Angelo A Gaddi A Ciccarelli L Piccinni MN Effects of 1 year of treatment with pioglitazone or rosiglitazone added to glimepiride on lipoprotein (a) and homocysteine concentrations in patients with type 2 diabetes mellitus and metabolic syndrome: A multicenter, randomized, double-blind, controlled clinical trial Clin Ther 2006 28 679 88 16861090
  94. [123]Davidson JA McMorn SO Waterhouse BR Cobitz AR A 24-week, multicenter, randomized, double-blind, placebo-controlled, parallel-group study of the efficacy and tolerability of combination therapy with rosiglitazone and sulfonylurea in African American and Hispanic American patients with type 2 diabetes inadequately controlled with sulfonylurea monotherapy Clin Ther 2007 29 1900 14 18035190
  95. [124]Umayahara R Yonemoto T Kyou C Morishita K Ogawa T Taguchi Y Low-dose glimepiride with sitagliptin improves glycemic control without dose-dependency in patients with type 2 diabetes inadequately controlled on high-dose glimepiride Endocr J 2014 61 1163 70 25168659
  96. [125]Schernthaner G Rosas-Guzmán J Dotta F Guerci B Simó R Festa A Treatment escalation options for patients with type 2 diabetes after failure of exenatide twice daily or glimepiride added to metformin: Results from the prospective European Exenatide (EUREXA) study Diabetes Obes Metab 2015 17 689 98 25846577
  97. [126]Derosa G Cicero AF Gaddi A Ragonesi PD Fogari E Bertone G Metabolic effects of pioglitazone and rosiglitazone in patients with diabetes and metabolic syndrome treated with glimepiride: A twelve-month, multicenter, double-blind, randomized, controlled, parallel-group trial Clin Ther 2004 26 744 54 15220018
  98. [127]Meshram DM Langade DG Kinagi SB Naikwadi AA Morye V Chopra D Evaluation of efficacy and safety of fixed dose combination of glimepiride 2 mg plus pioglitazone 15 mg plus metformin SR 500 mg in the management of patients with type-2 diabetes mellitus J Indian Med Assoc 2005 103 447 50 16363204
  99. [128]Sola D Rossi L Schianca GP Maffioli P Bigliocca M Mella R Sulfonylureas and their use in clinical practice Arch Med Sci 2015 11 840 8 26322096 PMC4548036
  100. [129]Lebovitz HE Pasmantier R Combination insulin-sulfonylurea therapy Diabetes Care 1990 13 667 75 2192850
  101. [130]Groop LC Groop PH Stenman S Combined insulin-sulfonylurea therapy in treatment of NIDDM Diabetes Care 1990 13 Suppl 3 47 52 2209344
  102. [131]Zhou J Zheng F Guo X Yang H Zhang M Tian H Glargine insulin/gliclazide MR combination therapy is more effective than premixed insulin monotherapy in Chinese patients with type 2 diabetes inadequately controlled on oral antidiabetic drugs Diabetes Metab Res Rev 2015 31 725 33 25952634
  103. [132]Schiel R Müller UA Efficacy and treatment satisfaction of once-daily insulin glargine plus one or two oral antidiabetic agents versus continuing premixed human insulin in patients with type 2 diabetes previously on long-term conventional insulin therapy: The SWITCH pilot study Exp Clin Endocrinol Diabetes 2008 116 58 64 17973208
  104. [133]Janka HU Plewe G Busch K Combination of oral antidiabetic agents with basal insulin versus premixed insulin alone in randomized elderly patients with type 2 diabetes mellitus J Am Geriatr Soc 2007 55 182 8 17302653
  105. [134]Standl E Maxeiner S Raptis S Karimi-Anderesi Z Schweitzer MA HOE901/4009 Study Group Good glycemic control with flexibility in timing of basal insulin supply: A 24-week comparison of insulin glargine given once daily in the morning or at bedtime in combination with morning glimepiride Diabetes Care 2005 28 419 20 15677803
  106. [135]Olsson PO Lindström T Combination-therapy with bedtime nph insulin and sulphonylureas gives similar glycaemic control but lower weight gain than insulin twice daily in patients with type 2 diabetes Diabetes Metab 2002 28 272 7 12442064
  107. [136]Park CY Kang JG Chon S Noh J Oh SJ Lee CB Comparison between the therapeutic effect of metformin, glimepiride and their combination as an add-on treatment to insulin glargine in uncontrolled patients with type 2 diabetes PLoS One 2014 9 e87799 24614911 PMC3948620
  108. [137]Li CJ Zhang JY Yu DM Zhang QM Adding glimepiride to current insulin therapy increases high-molecular weight adiponectin levels to improve glycemic control in poorly controlled type 2 diabetes Diabetol Metab Syndr 2014 6 41 24650537 PMC3994470
  109. [138]Vos RC van Avendonk MJ Jansen H Goudswaard AN van den Donk M Gorter K Insulin monotherapy compared with the addition of oral glucose-lowering agents to insulin for people with type 2 diabetes already on insulin therapy and inadequate glycaemic control Cochrane Database Syst Rev 2016 9 CD006992 27640062 PMC6457595
  110. [139]Pugh JA Wagner ML Sawyer J Ramirez G Tuley M Friedberg SJ Is combination sulfonylurea and insulin therapy useful in NIDDM patients? A metaanalysis Diabetes Care 1992 15 953 9 1387073
  111. [140]Esposito K Ciotola M Maiorino MI Gualdiero R Schisano B Ceriello A Addition of neutral protamine lispro insulin or insulin glargine to oral type 2 diabetes regimens for patients with suboptimal glycemic control: A randomized trial Ann Intern Med 2008 149 531 9 18936501
  112. [141]Janka HU Plewe G Riddle MC Kliebe-Frisch C Schweitzer MA Yki-Järvinen H Comparison of basal insulin added to oral agents versus twice-daily premixed insulin as initial insulin therapy for type 2 diabetes Diabetes Care 2005 28 254 9 15677775
  113. [142]Wright A Burden AC Paisey RB Cull CA Holman RR U.K. Prospective Diabetes Study Group Sulfonylurea inadequacy: Efficacy of addition of insulin over 6 years in patients with type 2 diabetes in the U.K. Prospective diabetes study (UKPDS 57) Diabetes Care 2002 25 330 6 11815505
  114. [143]Yki-Järvinen H Ryysy L Nikkilä K Tulokas T Vanamo R Heikkilä M Comparison of bedtime insulin regimens in patients with type 2 diabetes mellitus. A randomized, controlled trial Ann Intern Med 1999 130 389 96 10068412
  115. [144]Holman RR Thorne KI Farmer AJ Davies MJ Keenan JF Paul S Addition of biphasic, prandial, or basal insulin to oral therapy in type 2 diabetes N Engl J Med 2007 357 1716 30 17890232
  116. [146]Stuart CA Gilkison CR Carlson RF Stuart CA Gilkison CR Carlson RF Effect of adding a sulfonylurea in patients with non-insulin-dependent diabetes mellitus previously well controlled with insulin Endocr Pract 1997 3 344 8 15251771
  117. [147]Riddle M Hart J Bingham P Garrison C McDaniel P Combined therapy for obese type 2 diabetes: Suppertime mixed insulin with daytime sulfonylurea Am J Med Sci 1992 303 151 6 1595776
  118. [148]Chale SS Swai AB Mujinja PG McLarty DG Must diabetes be a fatal disease in Africa? Study of costs of treatment BMJ 1992 304 1215 8 1515790 PMC1881760
  119. [149]Zhang Y McCoy RG Mason JE Smith SA Shah ND Denton BT Second-line agents for glycemic control for type 2 diabetes: Are newer agents better? Diabetes Care 2014 37 1338 45 24574345
  120. [150]Pan F Chernew ME Fendrick AM Impact of fixed-dose combination drugs on adherence to prescription medications J Gen Intern Med 2008 23 611 4 18288541 PMC2324153
  121. [151]Saini SD Schoenfeld P Kaulback K Dubinsky MC Effect of medication dosing frequency on adherence in chronic diseases Am J Manag Care 2009 15 e22 33 19514806
  122. [152]Meece J Improving medication adherence among patients with type 2 diabetes J Pharm Pract 2014 27 187 94 24375997
  123. [153]Bangalore S Kamalakkannan G Parkar S Messerli FH Fixed-dose combinations improve medication compliance: A meta-analysis Am J Med 2007 120 713 9 17679131
  124. [154]Blonde L San Juan ZT Fixed-dose combinations for treatment of type 2 diabetes mellitus Adv Ther 2012 29 1 3 22271157
  125. [155]Riddle M Combining sulfonylureas and other oral agents Am J Med 2000 108 Suppl 6a 15S 22S 10764846
  126. [157]Han S Iglay K Davies MJ Zhang Q Radican L Glycemic effectiveness and medication adherence with fixed-dose combination or coadministered dual therapy of antihyperglycemic regimens: A meta-analysis Curr Med Res Opin 2012 28 969 77 22494018
  127. [159]Drouin P Standl E Diamicron MR Study Group Gliclazide modified release: Results of a 2-year study in patients with type 2 diabetes Diabetes Obes Metab 2004 6 414 21 15479217
  128. [162]Canadian Diabetes Association Clinical Practice Guidelines Expert Committee Meneilly GS Knip A Tessier D Diabetes in the elderly Can J Diabetes 2013 Last accessed on 2015 Aug 11 37 Suppl 1 S184 90 Available from: http://www.canadianjournalofdiabetes.com/article/S1499-2671(13)00046-4/pdf 24070944
  129. [163]Onge ES Miller SA Motycka C DeBerry A A review of the treatment of type 2 diabetes in children J Pediatr Pharmacol Ther 2015 20 4 16 25859165 PMC4353199
  130. [164]Gottschalk M Danne T Vlajnic A Cara JF Glimepiride versus metformin as monotherapy in pediatric patients with type 2 diabetes: A randomized, single-blind comparative study Diabetes Care 2007 30 790 4 17392540
  131. [165]Fajans SS Brown MB Administration of sulfonylureas can increase glucose-induced insulin secretion for decades in patients with maturity-onset diabetes of the young Diabetes Care 1993 16 1254 61 8404429
  132. [166]Raile K Schober E Konrad K Thon A Grulich-Henn J Meissner T Treatment of young patients with HNF1A mutations (HNF1A-MODY) Diabet Med 2015 32 526 30 25483937
  133. [167]Thanabalasingham G Owen KR Diagnosis and management of maturity onset diabetes of the young (MODY) BMJ 2011 343 d6044 22012810
  134. [169]Oztekin O Durmaz E Kalay S Flanagan SE Ellard S Bircan I Successful sulfonylurea treatment of a neonate with neonatal diabetes mellitus due to a novel missense mutation, p.P1199L, in the ABCC8 gene J Perinatol 2012 32 645 7 22842804
  135. [170]Pearson ER Flechtner I Njølstad PR Malecki MT Flanagan SE Larkin B Switching from insulin to oral sulfonylureas in patients with diabetes due to kir6.2 mutations N Engl J Med 2006 355 467 77 16885550
  136. [171]Babenko AP Polak M Cavé H Busiah K Czernichow P Scharfmann R Activating mutations in the ABCC8 gene in neonatal diabetes mellitus N Engl J Med 2006 355 456 66 16885549
  137. [172]Sagen JV Raeder H Hathout E Shehadeh N Gudmundsson K Baevre H Permanent neonatal diabetes due to mutations in KCNJ11 encoding kir6.2: Patient characteristics and initial response to sulfonylurea therapy Diabetes 2004 53 2713 8 15448106
  138. [173]Codner E Flanagan SE Ugarte F García H Vidal T Ellard S Sulfonylurea treatment in young children with neonatal diabetes: Dealing with hyperglycemia, hypoglycemia, and sick days Diabetes Care 2007 30 e28 9 17337505 PMC7611808
  139. [174]Kavitha N De S Kanagasabai S Oral hypoglycemic agents in pregnancy: An update J Obstet Gynaecol India 2013 63 82 7 24431611 PMC3664692
  140. [175]Kalra B Gupta Y Singla R Kalra S Use of oral anti-diabetic agents in pregnancy: A pragmatic approach N Am J Med Sci 2015 7 6 12 25709972 PMC4325398
  141. [176]Nicholson W Bolen S Witkop CT Neale D Wilson L Bass E Benefits and risks of oral diabetes agents compared with insulin in women with gestational diabetes: A systematic review Obstet Gynecol 2009 113 193 205 19104375
  142. [178]Gutzin SJ Kozer E Magee LA Feig DS Koren G The safety of oral hypoglycemic agents in the first trimester of pregnancy: A meta-analysis. Can J Clin Pharmacol 2003 10 179 83 14712322
  143. [179]Azimova K San Juan Z Mukherjee D Cardiovascular safety profile of currently available diabetic drugs Ochsner J 2014 14 616 32 25598727 PMC4295739
  144. [180]Ioannidis I Diabetes treatment in patients with renal disease: Is the landscape clear enough? World J Diabetes 2014 5 651 8 25317242 PMC4138588
  145. [181]Rosenkranz B Profozic V Metelko Z Mrzljak V Lange C Malerczyk V Pharmacokinetics and safety of glimepiride at clinically effective doses in diabetic patients with renal impairment Diabetologia 1996 39 1617 24 8960852
  146. [182]van Dalem J Brouwers MC Stehouwer CD Krings A Leufkens HG Driessen JH Risk of hypoglycaemia in users of sulphonylureas compared with metformin in relation to renal function and sulphonylurea metabolite group: Population based cohort study BMJ 2016 354 i3625 27413017 PMC4948031
  147. [183]Arjona Ferreira JC Marre M Barzilai N Guo H Golm GT Sisk CM Efficacy and safety of sitagliptin versus glipizide in patients with type 2 diabetes and moderate-to-severe chronic renal insufficiency Diabetes Care 2013 36 1067 73 23248197 PMC3631833
  148. [185]Tolman KG Fonseca V Dalpiaz A Tan MH Spectrum of liver disease in type 2 diabetes and management of patients with diabetes and liver disease Diabetes Care 2007 30 734 43 17327353
  149. [186]Hassanein M Al-Arouj M Hamdy O Bebakar WM Jabbar A Al-Madani A Diabetes and Ramadan: Practical guidelines Diabetes Res Clin Pract 2017 126 303 16 28347497
  150. [187]Glimepiride in Ramadan (GLIRA) Study Group The efficacy and safety of glimepiride in the management of type 2 diabetes in Muslim patients during Ramadan Diabetes Care 2005 28 421 2 15677804
  151. [188]Hassanein M Abdallah K Schweizer A A double-blind, randomized trial, including frequent patient-physician contacts and Ramadan-focused advice, assessing vildagliptin and gliclazide in patients with type 2 diabetes fasting during Ramadan: The STEADFAST study Vasc Health Risk Manag 2014 10 319 26 24920915 PMC4045264
  152. [189]Brady EM Davies MJ Gray LJ Saeed MA Smith D Hanif W A randomized controlled trial comparing the GLP-1 receptor agonist liraglutide to a sulphonylurea as add on to metformin in patients with established type 2 diabetes during Ramadan: The treat 4 Ramadan trial Diabetes Obes Metab 2014 16 527 36 24373063
  153. [190]Azar ST Echtay A Wan Bebakar WM Al Araj S Berrah A Omar M Efficacy and safety of liraglutide compared to sulphonylurea during Ramadan in patients with type 2 diabetes (LIRA-Ramadan): A randomized trial Diabetes Obes Metab 2016 18 1025 33 27376711 PMC5095865
  154. [191]Malha LP Taan G Zantout MS Azar ST Glycemic effects of vildagliptin in patients with type 2 diabetes before, during and after the period of fasting in Ramadan Ther Adv Endocrinol Metab 2014 5 3 9 24696775 PMC3972999
  155. [192]Al Sifri S Basiounny A Echtay A Al Omari M Harman-Boehm I Kaddaha G The incidence of hypoglycaemia in Muslim patients with type 2 diabetes treated with sitagliptin or a sulphonylurea during Ramadan: A randomised trial Int J Clin Pract 2011 65 1132 40 21951832 PMC3253336
  156. [193]Almalki MH Alshahrani F Options for controlling type 2 diabetes during Ramadan Front Endocrinol (Lausanne) 2016 7 32 27148163 PMC4834520
  157. [194]Kalra S Bajaj S Gupta Y Agarwal P Singh SK Julka S Fasts, feasts and festivals in diabetes-1: Glycemic management during Hindu fasts Indian J Endocrinol Metab 2015 19 198 203 25729681 PMC4319259
  158. [196]Julka S Sachan A Bajaj S Sahay R Chawla R Agrawal N Glycemic management during Jain fasts Indian J Endocrinol Metab 2017 21 238 41 28217525 PMC5240069
  159. [200]Powers MA Bardsley J Cypress M Duker P Funnell MM Fischl AH Diabetes self-management education and support in type 2 diabetes: A joint position statement of the American Diabetes Association, the American association of diabetes educators, and the academy of nutrition and dietetics Diabetes Educ 2015 41 417 30 26047627

Cited by

Sorted by citations

Authors
Kalra, S., Bahendeka, S., Sahay, R., Ghosh, S., Md, F., Orabi, A., Ramaiya, K., Al Shammari, S., Shrestha, D., Shaikh, K., Abhayaratna, S., Shrestha, P., Mahalingam, A., Askheta, M., A. Rahim, A., Eliana, F., Shrestha, H., Chaudhary, S., Ngugi, N., Mbanya, J., Aye, T., Latt, T., Akanov, Z., Syed, A., Tandon, N., Unnikrishnan, A., Madhu, S., Jawa, A., Chowdhury, S., Bajaj, S., & Das, A.
Affiliations
  • Bharti Hospital (IN)
  • Nsambya Hospital (UG)
  • Institute of Post Graduate Medical Education and Research (IN)
  • Bangladesh Medical University (BD)
  • Zagazig University (EG)
  • Royal Hospital (OM)
  • Tawam Hospital (AE)
  • Yarsi University (ID)
  • Dhulikhel Hospital (NP)
  • ADK Hospital (MV)
  • Kenyatta National Hospital (KE)
  • Chellaram Hospital (IN)
  • University of Delhi (IN)
  • Motilal Nehru Medical College (IN)
  • Pondicherry Institute of Medical Sciences (IN)
Corresponding author
Kalra, Sanjay
ORCID
Venue
Indian Journal of Endocrinology and Metabolism
Publisher
Ovid Technologies (Wolters Kluwer Health)
Published
2018
Volume
22
Issue
1
Pages
132
ISSN
2230-8210 (ISSN-L)
DOI
10.4103/ijem.ijem_556_17
PMC
PMC5838894
OpenAlex
W2805520818
Cited by
101
References
12
Citations by year
2026: 6 · 2025: 18 · 2024: 18 · 2023: 14 · 2022: 9 · 2021: 7 · 2020: 14 · 2019: 12 · 2018: 3
FWCI
1.38
Type
journal article
Language
en
Open access
Licence
cc-by-nc-sa
Locations
  • Indian Journal of Endocrinology and Metabolism (publishedVersion, cc-by-nc-sa)
  • Europe PMC (PubMed Central) (publishedVersion, cc-by-nc-sa)
  • PubMed Central (publishedVersion, cc-by-nc-sa)
  • PubMed (publishedVersion)
  • DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
Topics
  • Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
  • Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Management and Research
  • Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes, Cardiovascular Risks, and Lipoproteins
Keywords
sulfonylureas, type 2 diabetes, combination therapy, glimepiride, gliclazide modified release, hypoglycemia, weight gain, drug safety, antidiabetic drugs, personalized treatment, patient education

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review